Biohaven Profit Margin 2016-2022 | BHVN

Current and historical gross margin, operating margin and net profit margin for Biohaven (BHVN) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Biohaven net profit margin as of September 30, 2022 is -108.04%.
Biohaven Annual Profit Margins
Biohaven Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.282B $0.463B
Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $154.040B 9.40
GSK (GSK) United Kingdom $72.263B 9.00
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.195B 19.11
Ginkgo Bioworks Holdings (DNA) United States $3.764B 0.00
Myovant Sciences (MYOV) United Kingdom $2.602B 0.00
Arcus Biosciences (RCUS) United States $1.675B 25.14
Emergent Biosolutions (EBS) United States $0.672B 5.28
ADC Therapeutics SA (ADCT) Switzerland $0.388B 0.00
Ambrx Biopharma (AMAM) United States $0.075B 0.00
Enzo Biochem (ENZ) United States $0.069B 0.00
Gelesis Holdings (GLS) United States $0.026B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00